Lisa Henderson discusses industry's advice on handling the potentially trial altering occurrence of EDC vendor merges.
Applied Clinical Trials has previously published opinion articles on what to do when your EDC vendor fails, as well as EDC rescue studies. Upcoming in August, we feature another article related to EDC rescue studies.
With the likelihood that your EDC vendor is going to merge with another company, what do experts suggest?
Alan S. Louie, PhD, and author of the latest Health Industry Insights report titled “eClinical Buyer’s Guide, Part 1, Electronic Data Capture,” which focuses on the EDC vendor landscape and says that consolidation within this segment will continue, recommends that any EDC buyer ask a vendor for a capabilities description as part of the RFP, especially in regard to its competitors.
Our own previous article, Common Ground for eCTD, suggests that a buyer also take a good look at the vendor’s financial stability.
For the consolidated company or merger situation, Steve Johnson, COO of OmniComm Systems-which acquired ERT’s EDC products in June-told Applied Clinical Trials that a concerted effort was key. Both OmniComm and ERT made sure the customer was first in mind and that they experience no disruption of technology. “We will continue to support the [ERT] technology. We do plan on taking the best of both product suites and developing a hybrid solution of next generation technology. And the customers will have the option to upgrade to that,” said Johnson.
But as far as rescue studies go, Louie says many vendors offer rescue-specific capabilities. “They are a little more high-touch and help the [sponsor] regain their confidence in the eClinical. Some large vendors can do that, and there are a number of smaller vendors who can do it also.” Louie adds, “There are concerns that having their vendors fail, they’ll have to spend more for integration.”
“Rescue trials are the last thing you want to do,” Johnson elaborated. “We’ve been involved in rescue studies; brought in when someone hasn’t been happy with their EDC vendor. We can do it. But it’s not easy.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.